Physician profile
Daniel B Lamphier
NPI 1710206321
$6,378.71
in general payments reported to CMS, 2019-2025
50 companies · $1,005 in 2025
The $1,005 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $967 · 2020: $842 · 2021: $806 · 2022: $610 · 2023: $1,118 · 2024: $1,031 · 2025: $1,005.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,153.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,532.16 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $427.85 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Amgen INC. | $426.77 | 2019-2024 | Repatha, Otezla, Prolia |
| Lilly USA, LLC | $412.38 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $381.14 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $336.78 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $322.86 | 2021-2025 | |
| Abbott Laboratories | $285.91 | 2019-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $264.53 | 2019-2025 | Gardasil 9, Dificid, Pneumovax 23 |
| Astellas Pharma US INC | $232.44 | 2019-2025 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $192.28 | 2019-2025 | Jardiance, Tradjenta |
| Takeda Pharmaceuticals U.S.A., INC. | $130.44 | 2019-2023 | Trintellix |
| Exact Sciences Corporation | $102.25 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $92.83 | 2024-2025 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $91.83 | 2019-2023 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Lamphier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.